GlaxoSmithKline/Texas Bio argatroban
Anticoagulant argatroban receives "approvable" letter from FDA July 20 for supplemental application seeking to expand the treatment population to patients who have or who are at risk of developing thrombosis associated with heparin-induced thrombocytopenia and are undergoing percutaneous coronary intervention. Argatroban is currently approved for the prophylaxis or treatment of thrombosis in patients with HIT. The sNDA was filed in December
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth